Literature DB >> 8130024

Circadian variation in fibrinolytic activity in patients with variant angina.

T Masuda1, H Ogawa, Y Miyao, Q Yu, I Misumi, T Sakamoto, H Okubo, K Okumura, H Yasue.   

Abstract

BACKGROUND: Coronary artery spasm induces activation of the coagulation system. Turnover and maintenance of thrombus depend not only on formation but also on lysis. The relation between coronary spasm and fibrinolytic system has not been elucidated.
OBJECTIVE: To examine whether there is impairment of or a circadian variation in fibrinolytic activity in patients with variant angina.
METHODS: Plasminogen activator inhibitor (PAI) activity and concentrations of tissue plasminogen activator (t-PA) antigen were measured in venous plasma samples taken at 2200, 0600, and 1400 and 24 h Holter tapes were recorded in 15 patients with variant angina, 12 patients with stable exertional angina, and 12 controls.
RESULTS: There were significant circadian variations in PAI activity and t-PA antigen with peak values at 0600 in all three groups. Mean (SEM) PAI activity (IU/ml) at 2200, 0600, and 1400 was 6.1 (1.1), 11.0 (1.3), and 4.4 (0.6) in the variant angina group; 1.8 (0.7), 5.6 (1.1), and 1.2 (0.3) in the stable exertional angina group; and 1.1 (0.5), 4.5 (0.8), and 0.7 (0.3) in the control group. Furthermore, both plasma PAI activity and t-PA antigen concentrations were significantly higher in the variant angina group than in the stable exertional angina group and the control group at each sampling time.
CONCLUSIONS: In patients with variant angina there was a circadian variation in fibrinolytic activity, which was lowest in the early morning, and impaired fibrinolytic activity particularly in the early morning, when attacks of angina occur most frequently.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8130024      PMCID: PMC483636          DOI: 10.1136/hrt.71.2.156

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  39 in total

1.  Coronary arterial spasm in Prinzmetal angina. Documentation by coronary arteriography.

Authors:  P B Oliva; D E Potts; R G Pluss
Journal:  N Engl J Med       Date:  1973-04-12       Impact factor: 91.245

2.  Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

Authors:  L A Erickson; M H Ginsberg; D J Loskutoff
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

3.  Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.

Authors:  C Zamarron; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1984-02-25       Impact factor: 5.157

4.  Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina.

Authors:  T Masuda; H Yasue; H Ogawa; I Misumi; T Sakamoto; H Okubo; Y Miyao; H Kato
Journal:  Am Heart J       Date:  1992-08       Impact factor: 4.749

5.  Prinzmetal's variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: documentation by coronary arteriography.

Authors:  H Yasue; M Touyama; H Kato; S Tanaka; F Akiyama
Journal:  Am Heart J       Date:  1976-02       Impact factor: 4.749

6.  Arteriographic evidence of coronary arterial spasm in acute myocardial infarction.

Authors:  P B Oliva; J C Breckinridge
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

7.  Quantification of coronary arterial narrowing at necropsy in acute transmural myocardial infarction. Analysis and comparison of findings in 27 patients and 22 controls.

Authors:  W C Roberts; A A Jones
Journal:  Circulation       Date:  1980-04       Impact factor: 29.690

8.  Fibrinopeptide A: a marker of acute coronary thrombosis.

Authors:  P R Eisenberg; L A Sherman; K Schectman; J Perez; B E Sobel; A S Jaffe
Journal:  Circulation       Date:  1985-05       Impact factor: 29.690

9.  Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

Authors:  I M Nilsson; H Ljungnér; L Tengborn
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

10.  Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina.

Authors:  A Maseri; A L'Abbate; G Baroldi; S Chierchia; M Marzilli; A M Ballestra; S Severi; O Parodi; A Biagini; A Distante; A Pesola
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

View more
  5 in total

1.  Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle.

Authors:  Frank A J L Scheer; Steven A Shea
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

2.  Circadian patterns of ST elevation myocardial infarction in the new millennium.

Authors:  Rajan Kanth; Sunitha Ittaman; Shereif Rezkalla
Journal:  Clin Med Res       Date:  2013-04-11

3.  Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.

Authors:  Katarina Lalić; Aleksandra Jotić; Nataša Rajković; Sandra Singh; Ljubica Stošić; Ljiljana Popović; Ljiljana Lukić; Tanja Miličić; Jelena P Seferović; Marija Maćešić; Jelena Stanarčić; Milorad Čivčić; Iva Kadić; Nebojša M Lalić
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

4.  Iodixanol Has a Favourable Fibrinolytic Profile Compared to Iohexol in Cardiac Patients Undergoing Elective Angiography: A Double-Blind, Randomized, Parallel Group Study.

Authors:  Andrew T Treweeke; Benjamin H Maskrey; Kirsty Hickson; John H Miller; Stephen J Leslie; Ian L Megson
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

5.  The potential hazard of drug-eluting stent-induced coronary vasospasm causing subacute stent thrombosis: a case report.

Authors:  Hiroki Shibutani; Yuzo Akita; Yumie Matsui; Masahiro Yoshinaga; Masahiro Karakawa
Journal:  BMC Cardiovasc Disord       Date:  2016-11-25       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.